The importance of personalizing therapy based on certain genetic characteristics to avoid side effects. This is what is highlighted in a study coordinated by Henk-Jan Guchelaar of the Leiden University Medical Center (LUMC) and published in the prestigious scientific journal The Lancet, in which around 7,000 patients in healthcare settings in seven countries of the European Union took part. Italy could not be missing, represented by the Oncological Reference Center of Aviano (Pordenone), where, with the support of the Medical Oncology and Oncological Radiotherapy structures, 1,232 patients were treated, with the collaboration, during the enrollment phase, of the hospitals Ca' Foncello of Treviso and San Filippo Neri of Rome. The mission of the European project funded by the Horizon 2020 program, 'PREemptive Pharmacogenomic testing for Preventing Adverse drug Reactions (PREPARE) study' is to provide all European citizens with correct treatment through the administration of suitable drugs. And, through DNA mapping, it is a possible challenge, however demanding. (Agonb)